New meta-analysis [1].
I had a series of posts on inflamation 2 years ago: [2] [3] [4] [5].
The basis problem of studies is that inflammation is used for prognosis - not as a signal for intervention.
A man may appear to be entirely healthy, but chronic sub-clinical inflammation is associated with poorer 5-year survival. Inflammation can be addressed.
Chronic inflammation is a signature of cancer. The culprit is the activation of NF-kB. NF-kB activation can be inhibited. Inflammation can be tamed.
In the new study:
"... pretreatment NLR {neutrophil-lymphocyte ratio}, PLR {platelet-lymphocyte ratio}, LMR {lymphocyte-monocyte ratio}, neutrophil, and monocyte counts may be effective predictive biomarkers for prognosis in patients with PCa."
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/309...
Cancer Cell Int. 2019 Mar 25;19:70. doi: 10.1186/s12935-019-0785-2. eCollection 2019.
Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis.
Peng H1, Luo X2.
Author information
1
Department of Urological Surgery, Zhoukou Central Hospital of Henan Province, No. 26 Renmin East Road, Chuanhui District, Zhoukou, 466000 China.
2
2State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Materials Science and Engineering, Donghua University, Shanghai, 201620 China.
Abstract
BACKGROUND:
Pretreatment inflammatory factors, including neutrophil, lymphocyte, platelet and monocyte counts as well as the ratios between them such as neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lymphocyte-monocyte ratio (LMR) have been suggested as potential prognostic predictors for patients with prostate cancer (PCa). However, the prognostic effects remain controversial. Therefore, the goal of this study was evaluate the prognostic values of these markers for PCa patients using a meta-analysis.
METHODS:
Potentially relevant publications in PubMed and Cochrane Library were searched. Pooled hazard ratio (HR) with 95% confidence interval (CI) for overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), recurrence free survival (RFS) and distant metastases-free survival (DMFS) were determined using a fixed or random effects model by STATA 13.0 software.
RESULTS:
Thirty-two studies involving 21,949 participants were included. Our pooled results demonstrated that a high pretreatment NLR (HR = 1.55, 95% CI 1.37-1.76), PLR (HR = 1.72; 95% CI 1.36-2.18), neutrophil (HR = 1.10; 95% CI 1.03-1.18 and monocyte counts (HR = 2.25; 95% CI 1.67-3.05) predicted inferior OS, while elevated pretreatment LMR (HR = 2.27; 95% CI 1.76-2.94) was correlated with favorable OS. Furthermore, the higher NLR (HR = 1.62; 95% CI 1.29-2.04) and monocyte counts (HR = 1.75; 95% CI 1.36-2.25), but lower LMR predicted worse PFS (HR = 2.18; 95% CI 1.58-3.02); poor RFS was only associated with NLR (HR = 1.12; 95% CI 1.04-1.20). The subgroup analysis showed that the higher NLR may be a predictive factor for OS only in patients with mCRPC and undergoing chemotherapy; while the higher PLR was only significantly associated with OS in localized PCa regardless of treatment.
CONCLUSION:
This meta-analysis reveals that pretreatment NLR, PLR, LMR, neutrophil, and monocyte counts may be effective predictive biomarkers for prognosis in patients with PCa.
KEYWORDS:
Inflammatory markers; Meta-analysis; Prognosis; Prostate cancer
PMID: 30962764 PMCID: PMC6434630 DOI: 10.1186/s12935-019-0785-2
[2] healthunlocked.com/advanced...
[3] healthunlocked.com/advanced...